Implied SCHB Analyst Target Price: $25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $25.46, indicating a potential upside of 17.83% from its current trading price of $21.61. Notable underlying holdings with significant upside include Rapport Therapeutics Inc (RAPP), IDEAYA Biosciences Inc (IDYA), and Denali Therapeutics Inc (DNLI).
Investor Research Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 36.010
Low
30.00
Averages
49.86
High
79.00
Current: 36.010
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
